June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Three-Year Clinical Outcomes of Polypoidal Choroidal Vasculopathy Treatment Based on Early Polypoidal Lesion Regression: Swept-Source Optical Coherence Tomography Angiography Analysis
Author Affiliations & Notes
  • Sejun Park
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Junwoo Lee
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Jong Beom Park
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Kiyoung Kim
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Eung Suk Kim
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Seung-Young Yu
    Kyung Hee University Medical Center, Dongdaemun-gu, Seoul, Korea (the Republic of)
  • Footnotes
    Commercial Relationships   Sejun Park None; Junwoo Lee None; Jong Beom Park None; Kiyoung Kim None; Eung Suk Kim None; Seung-Young Yu None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 2564. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sejun Park, Junwoo Lee, Jong Beom Park, Kiyoung Kim, Eung Suk Kim, Seung-Young Yu; Three-Year Clinical Outcomes of Polypoidal Choroidal Vasculopathy Treatment Based on Early Polypoidal Lesion Regression: Swept-Source Optical Coherence Tomography Angiography Analysis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):2564.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the three-year clinical outcomes of polypoidal choroidal vasculopathy (PCV) treatment based on early polypoidal lesion regression according to the changes of swept-source optical coherence tomography angiography (SS-OCTA) features of polypoidal lesion.

Methods : Medical records and imaging data of 23 eyes of PCV patients with more than three years of follow-up were reviewed retrospectively. Best-corrected visual acuity (BCVA), central subfield thickness (CST), subfoveal choroidal thickness (SFCT), and the number of intravitreal injections were analyzed at the time of diagnosis, after three months, one year, two years, and three years. According to SS-OCTA-defined polypoidal lesion regression at three months after the first intravitreal injection, patients were divided into two groups: the regression group and the persistent group.

Results : Patients in the persistent group had significantly more hypertension than the regression group. BCVA was significantly different in the regression group (14 eyes) compared with the persistent group (9 eyes) after treatment in the first (p = 0.023) and second years (p = 0.033). The number of intravitreal injections during the first (p = 0.016) and second (p = 0.039) years were significantly high in the persistent group. The change in number of persistent polypoidal lesions at three months in the first year significantly correlated with the BVCA at one year (r=0.482, p = 0.019) and two years (r=0.517, p = 0.011).

Conclusions : Eyes with early regression of polypoidal lesions showed better visual outcome with a lower number of intravitreal injections. Early polypoidal lesion regression after treatment may be a predictor of clinical outcomes. The effect of hypertension and other systemic diseases should be evaluated in a large number of patients.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×